Is first-line single-agent mitoxantrone in the treatment ofhigh-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

Publication | Closed Access

DOI

Citations

References

2002

Year

E. Heidemann, Herbert Stoeger, Rainer Souchon, W. D. Hirschmann, H. Bodenstein, C. Oberhoff, Jörg Fischer, Markus Schulze, Michael Clemens, Reinhard Andreesen,

Annals of Oncology

Breast OncologyOncologyCombination ChemotherapyHigher QualityMedicineClinical TrialsBreast CancerPharmacotherapyFirst-line Single-agent MitoxantroneMetronomic ChemotherapyCancer TreatmentPharmacology